Literature DB >> 1356934

Protection against Vibrio cholerae El Tor infection by specific antibodies against mannose-binding hemagglutinin pili.

J Osek1, A M Svennerholm, J Holmgren.   

Abstract

Both specific polyclonal antiserum and monoclonal antibodies against mannose-binding hemagglutinin fimbriae of Vibrio cholerae (mannose-sensitive hemagglutinin [MSHA]) were shown to protect against experimental cholera caused by vibrios of the El Tor biotype in the infant mouse and in the rabbit intestinal loop models. MSHA-specific Fab immunoglobulin fragments were also protective. No protective effect was observed against challenge with V. cholerae O1 of the classical biotype. These results suggest that MSHA pili play an important role in the pathogenesis of cholera caused by the El Tor biotype of V. cholerae and that induction of intestinal anti-MSHA immunity may be a worthwhile additional objective in the development of oral cholera vaccines.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1356934      PMCID: PMC258256          DOI: 10.1128/iai.60.11.4961-4964.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Identification of a mannose-binding pilus on Vibrio cholerae El Tor.

Authors:  G Jonson; J Holmgren; A M Svennerholm
Journal:  Microb Pathog       Date:  1991-12       Impact factor: 3.738

2.  Morphological studies on fimbriae expressed by Vibrio cholerae 01.

Authors:  R H Hall; P A Vial; J B Kaper; J J Mekalanos; M M Levine
Journal:  Microb Pathog       Date:  1988-04       Impact factor: 3.738

3.  Intestinal fluid accumulation induced by oral challenge with Vibrio cholerae or cholera toxin in infant mice.

Authors:  V Baselski; R Briggs; C Parker
Journal:  Infect Immun       Date:  1977-03       Impact factor: 3.441

4.  Expression and detection of different biotype-associated cell-bound haemagglutinins of Vibrio cholerae O1.

Authors:  G Jonson; J Sanchez; A M Svennerholm
Journal:  J Gen Microbiol       Date:  1989-01

5.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

6.  A method for studies of an El Tor-associated antigen of Vibrio cholerae O1.

Authors:  A M Svennerholm; G Johnson; C Yan
Journal:  FEMS Microbiol Lett       Date:  1991-04-15       Impact factor: 2.742

7.  The study of intestinal immunity against V. cholerae: purification of V. cholerae El Tor haemagglutinin and the protective role of its antibody in experimental cholera.

Authors:  W Chaicumpa; N Atthasishtha
Journal:  Southeast Asian J Trop Med Public Health       Date:  1979-03       Impact factor: 0.267

8.  Experimental studies on cholera immunization. 4. The antibody response to formalinized Vibrio cholerae and purified endotoxin with special reference to protective capacity.

Authors:  A M Svennerholm
Journal:  Int Arch Allergy Appl Immunol       Date:  1975

9.  Characterization and distribution of the hemagglutinins produced by Vibrio cholerae.

Authors:  L F Hanne; R A Finkelstein
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

10.  Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up.

Authors:  J D Clemens; D A Sack; J R Harris; F Van Loon; J Chakraborty; F Ahmed; M R Rao; M R Khan; M Yunus; N Huda
Journal:  Lancet       Date:  1990-02-03       Impact factor: 79.321

View more
  12 in total

1.  Immune response to the mannose-sensitive hemagglutinin in patients with cholera due to Vibrio cholerae O1 and O0139.

Authors:  F Qadri; G Jonson; Y A Begum; C Wennerås; M J Albert; M A Salam; A M Svennerholm
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

2.  Differential expression of the ToxR regulon in classical and E1 Tor biotypes of Vibrio cholerae is due to biotype-specific control over toxT expression.

Authors:  V J DiRita; M Neely; R K Taylor; P M Bruss
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

Review 3.  Cholera.

Authors:  J B Kaper; J G Morris; M M Levine
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

4.  Genomic sequence and receptor for the Vibrio cholerae phage KSF-1phi: evolutionary divergence among filamentous vibriophages mediating lateral gene transfer.

Authors:  Shah M Faruque; Iftekhar Bin Naser; Kazutaka Fujihara; Pornphan Diraphat; Nityananda Chowdhury; M Kamruzzaman; Firdausi Qadri; Shinji Yamasaki; A N Ghosh; John J Mekalanos
Journal:  J Bacteriol       Date:  2005-06       Impact factor: 3.490

5.  Immune mechanisms and protective antigens of Vibrio cholerae serogroup O139 as a basis for vaccine development.

Authors:  G Jonson; J Osek; A M Svennerholm; J Holmgren
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

6.  Relative significance of mannose-sensitive hemagglutinin and toxin-coregulated pili in colonization of infant mice by Vibrio cholerae El Tor.

Authors:  S R Attridge; P A Manning; J Holmgren; G Jonson
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

Review 7.  Epidemiology, genetics, and ecology of toxigenic Vibrio cholerae.

Authors:  S M Faruque; M J Albert; J J Mekalanos
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

8.  The maltose regulon of Vibrio cholerae affects production and secretion of virulence factors.

Authors:  H Lång; G Jonson; J Holmgren; E T Palva
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

9.  Role of antibodies against biotype-specific Vibrio cholerae pili in protection against experimental classical and El Tor cholera.

Authors:  J Osek; G Jonson; A M Svennerholm; J Holmgren
Journal:  Infect Immun       Date:  1994-07       Impact factor: 3.441

10.  Carbohydrate-dependent binding of the cell-free hemagglutinin of Vibrio cholerae to glycoprotein and glycolipid.

Authors:  N Saha; K K Banerjee
Journal:  J Bacteriol       Date:  1995-02       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.